ロード中...
Design of a transdermal formulation containing raloxifene nanoparticles for osteoporosis treatment
PURPOSE: In the clinical setting, raloxifene, a second-generation selective estrogen receptor modulator, is administered orally; however, the bioavailability (BA) is only 2% because of its poor solubility in aqueous fluids and its extensive first-pass metabolism. Therefore, it is expected that the d...
保存先:
| 出版年: | Int J Nanomedicine |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6135211/ https://ncbi.nlm.nih.gov/pubmed/30233182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S173216 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|